361 Capital’s PTC Therapeutics PTCT Stock Holding History

361 Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-53,599	Closed	-$1.45M	–	379
2018 Q1	$1.45M	Buy	+53,599	New	+$1.36M	0.36%	147
2017 Q4	–	Sell	-89,600	Closed	-$1.79M	–	289
2017 Q3	$1.79M	Buy	+89,600	New	+$1.75M	0.34%	160

Other funds holding PTCT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

361 Capital's PTCT Position: Q2 2018 in Review

361 Capital sold out of PTC Therapeutics (PTCT) in Q2 2018, closing a stake of 53,599 shares — an estimated $1.45M sold.

361 Capital first reported a position in PTCT in Q3 2017 and held it in 2 quarters. The position peaked at $1.79M in Q3 2017. 166 funds tracked by Wall St. Rank hold PTCT as of Q2 2018.

361 Capital reported no remaining PTC Therapeutics position as of Q2 2018 after selling out during the quarter.
361 Capital sold 53,599 PTC Therapeutics shares in Q2 2018, an estimated $1.45M.
361 Capital first reported a position in PTC Therapeutics in Q3 2017 and held it in 2 quarters.
361 Capital's PTC Therapeutics position peaked at $1.79M in Q3 2017.
166 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2018.

Based on 361 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.